

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocybine,Imipramine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Details : Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Psilocybine,Imipramine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Imipramine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions
Details : Imipramine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2010
Lead Product(s) : Imipramine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Imipramine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Pfizer Inc | Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Imipramine and Pregabalin Combination in Painful Polyneuropathy
Details : Imipramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Polyneuropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2010
Lead Product(s) : Imipramine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc | Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
